Ieramilimab

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors[1].

Product Specifications

CAS Number

[2137049-37-5]

Product Name Alternative

LAG525; IMP701; Hu5A8

UNSPSC

12352203

Target

LAG-3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ieramilimab.html

Purity

98.24

Solubility

H2O

Smiles

[Ieramilimab]

Molecular Weight

(146.78 kDa)

References & Citations

[1]Patrick Schöffski, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022 Feb;10 (2) :e003776. |[2]Ghasemi K. Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy. Pathol Res Pract. 2025 Oct;274:156163.